Log in to save to my catalogue

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2354258648

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In women with HER2-positive metastatic breast cancer who had previously received HER2-targeted therapy, tucatinib, a new selective inhibitor of the HER2 tyrosine kinase, was added to trastuzumab and capecitabine and compared with trastuzumab and capecitabine plus placebo. Progression-free survival at 1 year was 33% with tucatinib and 12% with place...

Alternative Titles

Full title

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2354258648

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2354258648

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1914609

How to access this item